Trump is not vowing to abolish the FDA. Biopharma expects a modest boost in acquisitions and mergers, while FDA observers expect more oversight on things like compulsory childhood vaccines and mRNA vaccines, whilst other technologies, (perhaps like dendritic cell cancer vaccines, with safety data going back 20 years), might be in line for more favorable review. One can’t underestimate future and current octogenarians Trump’s and Goldman’s forty year connection.
Market Data 
Markets 
AI
